Overview
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Choriocarcinoma
- Chronic Lymphocytic Leukemia
- Ewing's Sarcoma
- Gestational Trophoblastic Neoplasia
- Hepatoblastomas
- Hodgkin's Lymphoma
- Immune Thrombocytopenia (ITP)
- Kaposi's Sarcoma
- Multiple Myeloma (MM)
- Neuroblastoma (NB)
- Non-Hodgkin's Lymphoma (NHL)
- Ovarian germ cell tumour
- Pheochromocytoma
- Relapsed Acute Lymphoblastic Leukemia (ALL)
- Retinoblastoma
- Rhabdomyosarcomas
- Small Cell Lung Cancer (SCLC)
- Wilms' tumor
- Advanced Thymoma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/18 | Phase 1 | Recruiting | |||
2025/05/02 | Phase 2 | Recruiting | Jennifer Amengual | ||
2025/04/24 | Early Phase 1 | Not yet recruiting | C17 Council | ||
2025/04/09 | Phase 2 | Not yet recruiting | City of Hope Medical Center | ||
2025/04/04 | Phase 3 | Not yet recruiting | |||
2025/02/11 | Phase 2 | Not yet recruiting | |||
2025/01/06 | Phase 1 | Recruiting | Sun Yat-sen University | ||
2024/12/17 | Phase 2 | Not yet recruiting | |||
2024/12/06 | Phase 1 | Recruiting | Theodore Laetsch | ||
2024/12/05 | Phase 3 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Hospira, Inc. | 61703-309 | INTRAVENOUS | 1 mg in 1 mL | 2/3/2023 | |
| Hospira, Inc. | 61703-309 | INTRAVENOUS | 1 mg in 1 mL | 2/1/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| VINRACINE INJ. 1 mg/ml | SIN10319P | INJECTION | 1 mg/ml | 10/29/1998 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Vincristine Sulfate Injection | 国药准字H20243689 | 化学药品 | 注射剂 | 5/15/2024 | |
| Vincristine Sulfate Injection | 国药准字H20233225 | 化学药品 | 注射剂 | 2/28/2023 | |
| Vincristine Sulfate for Injection | 国药准字H20043326 | 化学药品 | 注射剂 | 6/4/2020 | |
| Vincristine Sulfate for Injection | 国药准字H20058597 | 化学药品 | 注射剂 | 11/22/2022 | |
| Vincristine Sulfate for Injection | 国药准字H44022399 | 化学药品 | 注射剂(冻干) | 4/10/2020 | |
| Vincristine Sulfate for Injection | 国药准字H44021772 | 化学药品 | 注射剂(冻干) | 9/27/2019 | |
| Vincristine Sulfate for Injection | 国药准字H20068151 | 化学药品 | 注射剂 | 3/9/2021 | |
| Vincristine Sulfate for Injection | 国药准字H32026431 | 化学药品 | 注射剂 | 8/21/2020 | |
| Vincristine Sulfate for Injection | 国药准字H20045032 | 化学药品 | 注射剂 | 9/10/2020 | |
| Vincristine Sulfate for Injection | 国药准字H14020811 | 化学药品 | 注射剂 | 7/28/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| HOSPIRA VINCRISTINE SULFATE 5mg/5mL Injection Vial | 47250 | Medicine | A | 1/31/1994 | |
| Hospira Vincristine Sulfate Injection, USP 5mg/5mL vial | 74646 | Medicine | A | 5/31/2000 | |
| Hospira Vincristine Sulfate 1 mg/1mL injection USP | 144059 | Medicine | A | 8/30/2007 | |
| Hospira Vincristine Sulphate Injection, 2 mg/2 mL vial | 142605 | Medicine | A | 7/30/2007 | |
| Hospira Vincristine Sulphate 5 mg/5 mL Injection vial (preserved) | 191421 | Medicine | A | 11/2/2011 | |
| Vincristine Sulfate Injection 1 mg in 1 mL (6) | 325642 | Medicine | A | 10/28/2019 | |
| Vincristine Sulfate Injection 2 mg in 2 mL (2) | 324908 | Medicine | A | 10/15/2019 | |
| DBL VINCRISTINE SULFATE 2mg/2mL Injection Vial | 47249 | Medicine | A | 1/31/1994 | |
| Hospira Vincristine Solution Injection, 2 mg/2 mL vial | 142507 | Medicine | A | 7/25/2007 | |
| Hospira Vincristine Sulfate 2 mg/2 mL injection USP | 142501 | Medicine | A | 7/25/2007 |
Help Us Improve
Your feedback helps us provide better drug information and insights.